A Note on CBD: It's All in a Name. Issue 3 (22nd February 2019)

• Record Type: Journal Article
• Authors: Clark, H. Westley
• Is Part Of: Brown University child & adolescent psychopharmacology update. Volume 21:Issue 3(2019)
• Page Start: 5
• Page End: 6
• Publication Date: 2019-02-22
• Subjects: Pediatric psychopharmacology -- Periodicals; Psychopharmacology -- Periodicals; 615.78083
• DOI: 10.1002/cpu.30378
• Languages: English
• ISSNs: 1527-8395

Abstract

Abstract : I recently saw an article with the following title: "Medical cannabis relieves symptoms in children with autism." On reading it, I realized that the Drug Target Review was talking about cannabidiol, otherwise known as CBD, not THC (tetrahydrocannabinol, the psychoactive ingredient in cannabis). I also realized the words cannabis and marijuana are no longer useful in talking about marijuana now that CBD has been moved to Schedule V of the Controlled Substances Act when manufactured by GW Pharmaceuticals. Still, it is common to see CBD lumped with the hundreds of other cannabinoids, especially if not produced by a Food and Drug Administration (FDA)¬–approved pharmaceutical company where it is still classified as Schedule I by the Drug Enforcement Administration (DEA). I think this has implications for popular understanding and clinical utility.